AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12487386
Drug: Antiretroviral therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapies prescribed as part of the trial
Trial: 12487386
Drug: Adverse clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse clinical events (e.g., dermatological, gastrointestinal symptoms)
Trial: 9772328
Drug: Concomitant vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant vaccination (both vaccines administered simultaneously)
Trial: 9772328
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine (single injection of both vaccines mixed)
Trial: 9772328
Drug: Monovalent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccines (each vaccine administered alone)
Trial: 2590611
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg intravenous)
Trial: 2590611
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate (600 mg intravenous)
Trial: 2590611
Drug: Vehicle (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control for aspirin infusion)
Trial: 184978
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH gel (80 units once weekly or 80 units twice weekly)
Trial: 31610099
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (10 mg rivaroxaban tablet)
Trial: 31331789
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg up to 150 mg every 2 weeks for COMBO I & II or 150 mg every 2 weeks for LONG TERM)
Trial: 28481893
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (augmented treatment as usual)
Trial: 19195785
Drug: CR-oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR-oxycodone
Trial: 12643328
Drug: PEG-Hirudin (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Hirudin (i.v. bolus of 0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Trial: 12643328
Drug: ASA (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (325 mg)
Trial: 12643328
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of ASA and PEG-Hirudin
Trial: 12643328
Drug: PEG-Hirudin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Hirudin (0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Trial: 22300506
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 mcg/day
Trial: 22300506
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1000 mcg/day
Trial: 22300506
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 mcg/day and 1000 mcg/day
Trial: 15598978
Drug: Prolonged rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times)
Trial: 15598978
Drug: Standard schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard schedule (375 mg/m2 weekly x 4) followed by no further treatment
Trial: 15598978
Drug: Prolonged rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times) in pretreated patients
Trial: 15598978
Drug: Standard schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard schedule (375 mg/m2 weekly x 4) in pretreated patients
Trial: 11777366
Drug: Long-term very
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term very low doses of prednisone
Trial: 9504939
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg every eight hours)
Trial: 9504939
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g every six hours)
Trial: 3124618
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin
Trial: 3124618
Drug: Subcutaneous buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buserelin
Trial: 23953605
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg/day) + imidafenacin (0.1 mg 2 times a day)
Trial: 23953605
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg/day) alone
Trial: 19174069
Drug: Enteral diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral diet supplements with arginine (group I)
Trial: 16306030
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (nelfinavir, stavudine, didanosine, twice-daily)
Trial: 16306030
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (nevirapine, didanosine, lamivudine, once-daily)
Trial: 16306030
Drug: Regimen C
RxNorm normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C (saquinavir, ritonavir, didanosine, lamivudine, once-daily)
Trial: 7582277
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 360 mg triamcinolone intramuscularly
Trial: 7582277
Drug: Placebo triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo triamcinolone followed by low-dose oral methotrexate (7.5 mg followed by 15 mg weekly)
Trial: 1932648
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus, followed by 2 mg/min infusion)
Trial: 1932648
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline bolus and infusion)
Trial: 26348767
Drug: Cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol (CF) intake (450 mg bi-daily for 1 month)
Trial: 19732408
Drug: Regular counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular counseling and a treatment assistant
Trial: 12608650
Drug: Deflazacort (DFZ)
DrugBank: Deflazacort (DB11921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deflazacort (DFZ) treatment for one year
Trial: 2792658
Drug: Intravenous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ethanol administration (0.15 g/kg)
Trial: 2792658
Drug: Oral ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ethanol administration (0.15 g/kg)
Trial: 2792658
Drug: Intraduodenal ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal ethanol administration (0.15 g/kg)
Trial: 1017533
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate ointment
Trial: 29607554
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate ointment
Trial: 23617482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bone suppression and CAD
Trial: 21518596
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg/d)
Trial: 21518596
Drug: Nadroparin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (0.1 ml/10 kg q12 h)
Trial: 17137026
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg twice a day intravenously and then orally, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Trial: 17137026
Drug: Piperacillin/tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4 g/0.5 g three times a day, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Trial: 12924687
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) in a group format, 14 sessions, small groups of 4 to 6 participants
Trial: 8684876
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of Oka/Merck varicella vaccine
Trial: 8684876
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of Oka/Merck varicella vaccine
Trial: 1654074
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (further six courses)
Trial: 6222858
Drug: Moxalactam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (10 mg/kg)
Trial: 6222858
Drug: Cefazolin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (10 mg/kg)
Trial: 31925817
Drug: P218 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (10 mg)
Trial: 31925817
Drug: P218 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (30 mg)
Trial: 31925817
Drug: P218 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (100 mg)
Trial: 31925817
Drug: P218 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (250 mg)
Trial: 31925817
Drug: P218 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (500 mg)
Trial: 31925817
Drug: P218 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (750 mg)
Trial: 31925817
Drug: P218 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (1000 mg)
Trial: 31925817
Drug: P218 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P218 (250 mg) with food
Trial: 31401653
Drug: Post-treatment effects
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment effects
Trial: 31332901
Drug: Inhaled allergens
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled allergens
Trial: 26147820
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg intranasal midazolam as premedication
Trial: 23529993
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1200 mg n-3 long chain polyunsaturated fatty acids)
Trial: 19077149
Drug: Laser Doppler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser Doppler flowmetry (LDF) used to assess bone vascularity during implant insertion.
Trial: 17726273
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg levodopa
Trial: 11367872
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T) 3 x 150 mg
Trial: 11367872
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (R) 3 x 150 mg
Trial: 9438894
Drug: Lidocaine 50
RxNorm normalized name: lidocaine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 50 mg
Trial: 9438894
Drug: Lidocaine 200
RxNorm normalized name: lidocaine 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 200 mg
Trial: 8288408
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg twice daily, n = 52; 50 mg twice daily, n = 16)
Trial: 8288408
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg three times daily, n = 50; 60 mg three times daily, n = 16)
Trial: 26613820
Drug: Clomifene citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomifene citrate (100mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Trial: 26613820
Drug: Letrozole (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (5mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Trial: 20083625
Drug: Beta-blocker (metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (metoprolol succinate)
Trial: 10383563
Drug: OROS amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS amitriptyline (75 mg)
Trial: 10383563
Drug: IR amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR amitriptyline (25 mg every 8 h)
Trial: 10383563
Drug: IR amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR amitriptyline (3x25 mg at nighttime)
Trial: 20439595
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of Gardasil, Menactra, and Adacel (group A)
Trial: 20439595
Drug: Nonconcomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonconcomitant administration of Gardasil, Menactra, and Adacel (group B)
Trial: 16906786
Drug: Once-daily regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimen of efavirenz, emtricitabine and tenofovir DF (administered as individual agents)
Trial: 12707093
Drug: Subantimicrobial-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subantimicrobial-dose doxycycline (20-mg tablets taken twice daily for 6 months)
Trial: 11123824
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at 60 mg/kg divided into two doses
Trial: 11123824
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at a single dose of 40 mg/kg
Trial: 9181384
Drug: Amoxycillin/clavulanate (A/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d.
Trial: 9181384
Drug: Amoxycillin/clavulanate (A/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (A/C) 60/15 mg/kg/day given t.i.d.
Trial: 2418659
Drug: Bleomycin intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin intravesical instillation (60 mg on each treatment day)
Trial: 2418659
Drug: Bleomycin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin + Bestatin (60 mg per day)
Trial: 31849295
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (569 patients)
Trial: 30201679
Drug: Clinical decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical decision support (CDS) intervention implemented in family medicine clinics
Trial: 30201679
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (general internal medicine clinics)
Trial: 25403709
Drug: Individualised dietetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised dietetic advice and regular weekly follow-up (INT)
Trial: 12219472
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antioxidants and zinc
Trial: 12219472
Drug: Photodynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic treatment of certain forms of CNV
Trial: 12219472
Drug: Prophylactic laser
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic laser treatment of soft drusen maculopathy
Trial: 9926184
Drug: Tramadol (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (3.0 mg.kg‐1)
Trial: 9404175
Drug: Nalbuphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.3 mg.kg‐1)
Trial: 9926184
Drug: Saline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.2 ml.kg‐1)
Trial: 9926184
Drug: Pethidine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (1.5 mg.kg‐1)
Trial: 7486039
Drug: Cisatracurium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 60 s (Pilot Group A, n = 5)
Trial: 7486039
Drug: Cisatracurium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 30 s (Pilot Group B, n = 5)
Trial: 7486039
Drug: Cisatracurium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 5-10 s (Group C, n = 30)
Trial: 7486039
Drug: Vecuronium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.10 mg/kg, 2 x ED90) administered over 5-10 s (Group D, n = 30)
Trial: 23494656
Drug: rhLAMAN (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhLAMAN (recombinant human alpha-mannosidase) administered weekly via intravenous enzyme replacement therapy (ERT) for 12 months
Trial: 16424422
Drug: R-albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-albuterol
Trial: 12814158
Drug: Budesonide/formoterol single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol single inhaler (Symbicort Turbuhaler) 160/4.5 microg delivered dose, two inhalations bid
Trial: 1536399
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin solution
Trial: 6379911
Drug: Tendamistate 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tendamistate 400 mg
Trial: 31166390
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG), no surface treatment
Trial: 29425211
Drug: Bioactive Food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive Food Compound (BFC) 40 g daily
Trial: 24750471
Drug: Implant-supported partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported partial dentures (IRPDs)
Trial: 24750471
Drug: Implant-fixed partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-fixed partial dentures (IFPDs)
Trial: 18331607
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg bid)
Trial: 20590747
Drug: Voglibose (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.2 mg tid)
Trial: 15763454
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of oral sustained-release theophylline
Trial: 11884816
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol infusion (loading dose of 0.8 mg.kg(‐1) followed by continuous infusion of 30 microg.kg(‐1)min(‐1))
Trial: 2355819
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg; nBB)
Trial: 2355819
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg; sBB)
Trial: 2355819
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg; nBB)
Trial: 367086
Drug: i.v. verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. verapamil (0.15 mg/kg body weight)
Trial: 367086
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil (80 mg)
Trial: 367086
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil (240 mg)
Trial: 367086
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil (320 mg)
Trial: 367086
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil (400 mg)
Trial: 367086
Drug: chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chronic oral therapy with progressively increasing doses of verapamil
Trial: 26175087
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation (200 mg iron sucrose)
Trial: 19139440
Drug: IFN‐alpha‐2b 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks (arm A)